Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 6/20 | 0.36 |
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4354924 | 0.89 | HRH1 (0.42) | LMNAHRH1HTR2ATAAR1 | |
| SCHEMBL1263573 | 0.89 | AOC3 (0.48) | AOC3ESR1ESR2LMNAHRH1 | |
| SCHEMBL6110984 | 0.88 | POLB (0.41) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL3316490 | 0.88 | AOC3 (0.40) | AOC3ESR1ESR2LMNAHRH1 | |
| SCHEMBL9276354 | 0.87 | AOC3 (0.47) | AOC3ESR1ESR2LMNAHRH1 | |
| SCHEMBL15563657 | 0.86 | SIGMAR1 (0.41) | HTR2ASIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL17183765 | 0.86 | SIGMAR1 (0.41) | AOC3ESR1ESR2LMNAHRH1 | |
| SCHEMBL15061554 | 0.85 | LMNA (0.45) | LMNAHRH1HTR2ASIGMAR1TAAR1 | |
| SCHEMBL536776 | 0.85 | AOC3 (0.43) | AOC3ESR1ESR2LMNAHRH1 | |
| SCHEMBL536830 | 0.85 | LMNA (0.45) | LMNAHRH1HTR2ASIGMAR1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108186-A2 | PRODUCTION OF HYDROGEN FROM CARBOHYDRATES USING VIOLOGEN CATALYSTS | WATT POWER INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20210205199-A1 | Dermatological Cosmetic Composition Comprising an SDKP Peptide or an Analog Thereof | RPM DERMATOLOGIE (FR) | 2021-07-08 | — | — | US | disclosed |
| WO-2021107870-A1 | ANTIMICROBIAL AGENT, COATING FORMULATION, COMPOSITE SURFACE COATING AND METHODS OF PREPARING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-06-03 | — | — | WO | disclosed |
| EP-3239111-B1 | CURABLE COMPOSITION, TRANSFER FILM, FRONT PLATE OF IMAGE DISPLAY DEVICE, FRONT PLATE-INTEGRATED SENSOR, IMAGE DISPLAY DEVICE, AND MANUFACTURING METHOD FOR FRONT PLATE OF IMAGE DISPLAY DEVICE | FUJIFILM CORP (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-105764885-B | The production method of acid and free-radical generating agent and acid and free radical | 富士胶片和光纯药株式会社 | 2018-11-09 | — | — | CN | disclosed |
| US-10035927-B2 | Coloring composition for decoration, decorative material, base material having decorative material, transfer material, touch panel, and information display device | FUJIFILM CORPORATION (JP) | 2018-07-31 | — | — | US | disclosed |
| US-9988349-B2 | Direct stereospecific synthesis of unprotected aziridines from olefins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-05 | — | — | US | disclosed |
| EP-1753708-B1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3239111-A1 | CURABLE COMPOSITION, TRANSFER FILM, FRONT PLATE OF IMAGE DISPLAY DEVICE, FRONT PLATE-INTEGRATED SENSOR, IMAGE DISPLAY DEVICE, AND MANUFACTURING METHOD FOR FRONT PLATE OF IMAGE DISPLAY DEVICE | FUJIFILM Corporation (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9802902-B2 | Antifungal compound | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-10-31 | — | — | US | disclosed |
| EP-1278716-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-01-29 | — | — | EP | disclosed |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | KORNBERG BRIAN EDWARD (US) | 2003-01-23 | — | — | US | disclosed |
| US-20030004212-A1 | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1251128-A1 | Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists | WARNER-LAMBERT COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2002050070-A2 | PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2001094321-A1 | BICYCLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001092239-A1 | BICICLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTOGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001092204-A1 | CYCLOHEXYLAMINE DERIVATIVES AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001081295-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| US-4859759-A | Siloxane containing benzotriazolyl/tetraalkylpiperidyl substituent | KIMBERLY-CLARK CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004212-A1 | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | GLRB, GRIN1, GRIN2B | AOC3 4392/4885ESR1 1648/4885ESR2 1139/4885 |
| US-20210205199-A1 | Dermatological Cosmetic Composition Comprising an SDKP Peptide or an Analog Thereof | CUTA, SDAD1, SDCBP | AOC3 3261/4885ESR1 4638/4885ESR2 4312/4885 |
| US-20030018021-A1 | Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists | GRIN1, OPRD1, OPRM1 | AOC3 4650/4885ESR1 3014/4885ESR2 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.